secwatch.observer — SEC 8-K summary
======================================

Issuer:     ORAGENICS INC (OGEN)
CIK:        0001174940
Form:       8-K
Filed at:   2026-03-11T23:59:59+00:00
Accession:  0001493152-26-009682
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Oragenics gets HREC approval, starts Phase IIa site activation for ONP-002 in Australia; explores CNS asset acquisition
--------------------------------------------------------------------------------

- Received final HREC approval in Australia for Phase IIa trial of ONP-002 for concussion/mTBI.
- Completed first site initiation visit (SIV) for Phase IIa trial; two more sites in final RGO review.
- Phase IIa trial of 40 patients; first dose within 12 hours of injury; data readout expected before year-end 2026.
- Exploring discussions with third parties for potential acquisition of CNS assets focusing on brain health/recovery.
- No definitive agreements reached; platform expansion independent of Receptor.AI partnership.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226009682/0001493152-26-009682-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1174940/000149315226009682/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-26-009682

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer